Literature DB >> 25267898

Fibrates for primary prevention of cardiovascular disease events.

Alain J Nordmann1, Ignacio Ferreira-González2, Benjamin Kasenda1, Ramon Saccilotto1, Dirk Bassler3, Neera Bhatnagar4, Matthias Briel1.   

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the clinical benefit and harm of fibrates versus placebo or usual care or fibrates plus other lipid-modifying drugs versus other lipid-modifying drugs alone for the primary prevention of CVD events and mortality.

Entities:  

Year:  2012        PMID： 25267898      PMCID： PMC4176663          DOI： 10.1002/14651858.CD009753

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN： 1361-6137


  35 in total

Review 1.  Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis.

Authors:  J A Sterne; M Egger; G D Smith
Journal:  BMJ       Date:  2001-07-14

2.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

3.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

4.  European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).

Authors:  Ian Graham; Dan Atar; Knut Borch-Johnsen; Gudrun Boysen; Gunilla Burell; Renata Cifkova; Jean Dallongeville; Guy De Backer; Shah Ebrahim; Bjørn Gjelsvik; Christoph Herrmann-Lingen; Arno Hoes; Steve Humphries; Mike Knapton; Joep Perk; Silvia G Priori; Kalevi Pyorala; Zeljko Reiner; Luis Ruilope; Susana Sans-Menendez; Wilma Scholte Op Reimer; Peter Weissberg; David Wood; John Yarnell; Jose Luis Zamorano; Edmond Walma; Tony Fitzgerald; Marie Therese Cooney; Alexandra Dudina; Alec Vahanian; John Camm; Raffaele De Caterina; Veronica Dean; Kenneth Dickstein; Christian Funck-Brentano; Gerasimos Filippatos; Irene Hellemans; Steen Dalby Kristensen; Keith McGregor; Udo Sechtem; Sigmund Silber; Michal Tendera; Petr Widimsky; Jóse Luis Zamorano; Attila Altiner; Enzo Bonora; Paul N Durrington; Robert Fagard; Simona Giampaoli; Harry Hemingway; Jan Hakansson; Sverre Erik Kjeldsen; mogens Lytken Larsen; Giuseppe Mancia; Athanasios J Manolis; Kristina Orth-Gomer; Terje Pedersen; Mike Rayner; Lars Ryden; Mario Sammut; Neil Schneiderman; Anton F Stalenhoef; Lale Tokgözoglu; Olov Wiklund; Antonis Zampelas
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2007-09

Review 5.  Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

Authors:  Min Jun; Celine Foote; Jicheng Lv; Bruce Neal; Anushka Patel; Stephen J Nicholls; Diederick E Grobbee; Alan Cass; John Chalmers; Vlado Perkovic
Journal:  Lancet       Date:  2010-05-10       Impact factor: 79.321

6.  Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

Authors:  Thomas Thom; Nancy Haase; Wayne Rosamond; Virginia J Howard; John Rumsfeld; Teri Manolio; Zhi-Jie Zheng; Katherine Flegal; Christopher O'Donnell; Steven Kittner; Donald Lloyd-Jones; David C Goff; Yuling Hong; Robert Adams; Gary Friday; Karen Furie; Philip Gorelick; Brett Kissela; John Marler; James Meigs; Veronique Roger; Stephen Sidney; Paul Sorlie; Julia Steinberger; Sylvia Wasserthiel-Smoller; Matthew Wilson; Philip Wolf
Journal:  Circulation       Date:  2006-01-11       Impact factor: 29.690

7.  Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.

Authors:  David J Graham; Judy A Staffa; Deborah Shatin; Susan E Andrade; Stephanie D Schech; Lois La Grenade; Jerry H Gurwitz; K Arnold Chan; Michael J Goodman; Richard Platt
Journal:  JAMA       Date:  2004-11-22       Impact factor: 56.272

8.  The emergence of triglycerides as a significant independent risk factor in coronary artery disease.

Authors:  G Assmann; H Schulte; H Funke; A von Eckardstein
Journal:  Eur Heart J       Date:  1998-10       Impact factor: 29.983

9.  Global estimates of the prevalence of diabetes for 2010 and 2030.

Authors:  J E Shaw; R A Sicree; P Z Zimmet
Journal:  Diabetes Res Clin Pract       Date:  2009-11-06       Impact factor: 5.602

Review 10.  Safety considerations with fibrate therapy.

Authors:  Michael H Davidson; Annemarie Armani; James M McKenney; Terry A Jacobson
Journal:  Am J Cardiol       Date:  2006-12-08       Impact factor: 2.778
View more
  2 in total

Review 1.  Fibrates for secondary prevention of cardiovascular disease and stroke.

Authors:  Deren Wang; Bian Liu; Wendan Tao; Zilong Hao; Ming Liu
Journal:  Cochrane Database Syst Rev       Date:  2015-10-25

Review 2.  Fibrates for primary prevention of cardiovascular disease events.

Authors:  Tobias Jakob; Alain J Nordmann; Stefan Schandelmaier; Ignacio Ferreira-González; Matthias Briel
Journal:  Cochrane Database Syst Rev       Date:  2016-11-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.